AbbVie's Mixed Q3 Earnings: Skyrizi & Rinvoq Shine, Aesthetics Struggle
Update: 2025-11-07
Description
AbbVies Q3 earnings showcased a mixed bag for investors, with strong revenue growth from immunology and neuroscience products like Skyrizi and Rinvoq, but a significant drop in operating margin and challenges in the aesthetics segment. Despite beating estimates, the market reacted negatively, pushing the stock price down. CEO Rob Michael acknowledged economic conditions and emphasized core therapeutic areas performance. Analysts sought long-term guidance for Skyrizi and Rinvoq, and AbbVie plans to address aesthetics market softness through consumer confidence and new product launches. Future focus includes expanding labels for Rinvoq, Skyrizi, and tavapadon, alongside stabilization and growth in aesthetics demand and the impact of recent acquisitions and research investments.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
